
- Telehealth Visits

Mark Walters, MD
Pediatric Hematology-OncologyDivision Chief, Hematology, UCSF Benioff ChildrenÆs Hospitals- Telehealth Visits



Mark Walters, MD
Pediatric Hematology-OncologyDivision Chief, Hematology, UCSF Benioff ChildrenÆs Hospitals- Telehealth Visits
On this page
About me
Dr. Mark Walters is a hematologist-oncologist who cares for children with blood disorders and cancer, and specializes in blood and bone marrow transplants. He is director of the Pediatric Blood and Marrow Transplant Program at UCSF Benioff Children's Hospital Oakland.
Walters' research focuses on transplant and gene therapy for sickle cell disease and thalassemia – which are both red blood cell disorders that involve abnormalities of hemoglobin (the protein in red blood cells that carries oxygen). His goal is to offer a curative therapy to every child he treats. Because finding a healthy donor for sickle cell disease can be difficult, he also investigates methods that aim to correct the patient's own blood system through gene therapy and return the edited blood cells to the patient's circulation.
Walters earned his medical degree from the University of California, San Diego School of Medicine. He completed a residency in pediatrics at the University of Washington School of Medicine, followed by a fellowship in pediatric hematology-oncology at the Fred Hutchinson Cancer Research Center.
Education
Board Certification
- Pediatric Hematology-Oncology, American Board of Pediatrics
Fellowship
- Ped. Hema/Oncology, University of Washington School of Medicine GME
Residency
- Pediatrics, University of Washington School of Medicine GME
Internship
- Pediatrics, University of Washington School of Medicine GME
School
- MD, University of California San Diego School of Medicine
Academic Title
- Professor-in-Residence
Care Keywords
Services
- Pediatric Hematology-Oncology
Locations
Provider Research Listing
Browse clinical trials and publications by this provider
Clinical trials
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALLOpens in a new window
Recruiting
The primary objective of this study is the two Year Event-free Survival for patients with high-risk or recurrent B-ALL who proceed to HCT and who are NGS-MRD n...
Publications
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.
The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.
